Finding potential trillion-dollar companies can be as challenging as spotting a rare diamond in a sea of cubic zirconia. It’s not just about picking a handful of undervalued stocks and hoping for the best. The companies closest to achieving this remarkable feat often lurk just below the surface, overshadowed by the more high-profile giants like Apple and Microsoft.

These hidden gems, with valuations ranging from $536 billion to $856 billion, may hold the key to the next wave of trillion-dollar enterprises.

Berkshire Hathaway: Nearing the Trillion-Dollar Mark

Berkshire Hathaway (NYSE:BRK-A, NYSE:BRK-B) stands at a valuation of $856 billion, making it the frontrunner in the race to join the trillion-dollar club. The conglomerate’s significant holdings in Apple position it as a formidable contender. However, beyond this, Berkshire’s approach to value investing, under the astute guidance of Warren Buffett and the late Charlie Munger, sets it apart. As market volatility escalates, the shift towards value stocks plays to Berkshire’s advantage. A strategic investment in Berkshire embodies outsourced and meticulous value stock research, thanks to the rigorously scrutinized direct investments and holdings.

Timing also plays a role in this narrative. With speculation rife about an impending game-changing announcement in Berkshire’s upcoming earnings report, seizing the opportunity to invest in Berkshire today could prove to be a shrewd move.

The Rising Star: Eli Lilly on the Trillion-Dollar Horizon

Eli Lilly (NYSE:LLY) is not far behind Berkshire in the pursuit of trillion-dollar status, with a current valuation of $705 billion. Recent breakthroughs in two critical segments have propelled LLY on this trajectory, with no signs of slowing down.

The debut of LLY’s weight loss drug, Zepbound, in November 2023 sent shockwaves through the market, raking in a staggering $175.8 million in sales and showing no signs of losing momentum. With a third of adults overweight and two-fifths classified as obese, the national market demand for Zepbound presents a recurring revenue stream with virtually limitless potential for expansion, offering significant bottom line support for LLY.

Furthermore, a legacy drug, the diabetes medication Mounjaro, witnessed an unprecedented surge in sales. Despite logistical chain disruptions impeding its availability in late 2022, judicious pricing adjustments and stabilized supply resulted in Mounjaro contributing up to 25% of LLY’s top-line sales.

The Global Player: Taiwan Semiconductor’s Ascent toward Trillion-Dollar Territory

Taiwan Semiconductor (NYSE:TSM) represents the lone international contender on our list of potential trillion-dollar companies. With a valuation of $536 billion, TSM is steadily carving a path toward this elite club.

Innovative Companies on The Cusp of Trillion-Dollar Valuation

Taiwan Semiconductor Manufacturing Company (TSMC)

Taiwan Semiconductor Manufacturing Company, TSMC (NYSE: TSM), may not be a household name compared to the tech giants, but the company is a powerhouse in the chip industry. Analysts have consistently placed TSMC at the forefront of innovative chip manufacturers. The company plays a critical role in powering modern electronics and maintaining its position as a top U.S. supplier, despite efforts by legislators to bolster domestic semiconductor production.

The company’s remarkable financial discipline, with minimal debt and an impressive 40% net margin, positions it tenaciously amid market upheavals. TSMC’s resilience in the face of turbulence, particularly compared to other emerging market stocks, reflects its unwavering stability and promising trajectory towards achieving a trillion-dollar valuation.

Tesla (TSLA)

From hitting the trillion-dollar mark in 2021 and 2022 to the current valuation of $586 billion, Tesla (NASDAQ: TSLA) remains a compelling contender in the race to reach a trillion-dollar market cap. While the recent market cap decline has sparked concerns, Tesla’s history of high valuations and innovative approaches to challenges make it a strong candidate for surpassing the trillion-dollar threshold once again.

However, pivotal factors, such as cost-cutting measures and their impact on margins, will play a crucial role in determining whether Tesla can regain its trillion-dollar status. Moreover, the implications of Elon Musk’s diverse ventures, including his foray into social media with the acquisition and rebranding of Twitter, raise questions about his level of attention to Tesla, potentially affecting the stock’s valuation.

Broadcom (AVGO)

Broadcom (NASDAQ: AVGO), a key supplier to tech behemoth Apple, is rapidly gaining momentum with a valuation of $585 billion. The company’s strategic advancements, such as the recent expansion through a deal with VMware, are reducing its reliance on Apple, thereby fortifying its position for future growth. Notably, artificial intelligence is a significant driver of AVGO’s success, with recent AI-related developments adding $350 billion to its value.

As AI continues to shape the tech landscape, Broadcom’s proactive integration of AI into its operations positions it favorably for sustained growth. Analysts’ upbeat outlook and raised price targets further underscore the company’s potential to ascend to a trillion-dollar valuation, with one expert advocating a target price nearly 20% higher than the current levels.

Visa (V)

Visa (NYSE:V), a stalwart in the cashless payment processing industry, commands a significant 20% share of the global market. The company’s resilience and adaptability in an evolving financial landscape, characterized by a surge in digital currencies and online transactions, position it as a force to be reckoned with. Visa’s strategic foray into enterprise-level clients and its efforts to simplify corporate spending underpin its pioneering initiatives in a traditional market. This forward-thinking approach is pivotal as corporate credit continues to dominate overall revolving credit utilization and extends its influence.

With its consistent innovation and formidable market dominance, Visa emerges as a compelling candidate for the trillion-dollar club, underscoring its enduring relevance and potential for further growth in the digital era.

Novo Nordisk: The Race to Trillion-Dollar Status

Weight Loss Drugs and the Path to Trillion-Dollar Status

The thesis supporting Novo Nordisk (NYSE: NVO) becoming the next trillion-dollar company is similar to that of Eli Lilly’s, and, worth $536 billion, NVO isn’t too far behind. The world’s largest wealth fund agrees, saying recently that both Novo Nordisk and Eli Lilly are on track to trillion-dollar status. And, like LLY, Novo Nordisk’s path is lined with weight loss drugs that are proving increasingly popular.

Supply Issues and Sales

Though supply issues put some pressure on NVO’s weight loss drug Wegovy, that doesn’t mean sales will slow financially. Instead, since Wegovy trends toward the discretionary side of therapeutic treatment, expect pricing to increase and meet reduced supply as demand climbs. Like LLY, that’ll boost NVO’s bottom-line numbers and prove profitable once logistics stabilize and prospective customers flood the manufacturer.

Market Expansion and Future Growth

With as many as 15 million adults contributing to a $100 billion obesity treatment market by 2030, Novo Nordisk is well on its way to trillion-dollar status. Payment processing makes our lives easier, but the real money is in B2B spending. That’s a fact Visa happily embraces and one that contributes to its race to trillion-dollar status.